drugset / Trial / NCT06533579
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.
Timeline
- Start
- 2025-05-30
- Primary completion
- 2027-06
- Completion
- 2031-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | VNX-101 | Gene therapy (AAV / viral vector) | — | Intravenous |